[1] Saha A, CHATTERJEE S K, FOON K A. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigenspecific protective antitumor immunity. 2003(11)
[2] MEIJER S L, DOLS A, URBA W J. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. 2002(4)
[3] Salgia R, LYNCH T, SKARIN A. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. 2003(4). doi:10.1200/JCO.2003.03.091
[4] Dakappagari N K, PYLES J, PARIHAR R. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. 2003(8)
[5] Pertl U, WODRICH H, RUEHLMANN J M. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. 2003(2)
[6] Lou D, KOHLER H. Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide. 1998(5). doi:10.1038/nbt0598-458
[7] Antonia S J, SEIGNE J, DIAZ J. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. 2002(5)
[8] BRIONES J, TIMMERMAN J, LEVY R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. 2002(11)
[9] Asada H, KISHIDA T, HIRAI H. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. 2002(5). doi:10.1006/mthe.2002.0587
[10] YEI S, BARTHOLOMEW R M, PEZZOLI P. Novel membrane-bound GM-CSF vaccines for the treatment of cancer :generation and evaluation of mbGM-CSF mouse B16F10melanoma cell vaccine. 2002(9). doi:10.1038/sj.gt.3301803
[11] Jang Y J, NAM S Y, KIM M S. Simultaneous expression of allogenic class Ⅰ MHC and B7.1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity. 2002(1)
[12] Qian H N, LIU C Z, CAO S J. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN -gamma genes. 2002(1). doi:10.1046/j.1525-1438.2002.01060.x
[13] BRIONES J, TIMMERMAN J M, PANICALLI D L. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. 2003(7)
[14] Rieger R, KIPPS T J. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. 2003(14)
[15] NIKITINA E Y, CHADA S, MURO-CACHO C. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. 2002(9). doi:10.1038/sj.gt.3301670
[16] Okada H, POLLACK I F, LIEBERMAN F. Gene therapy of malignant gliomas:A pilot study of immunnzation with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. 2001(5). doi:10.1089/104303401300042528
[17] Panelli M C, WUNDERLICH J, JEFFRIES J. Phase 1 study in patient with metastatic melanima of immunization with dendritic cells presenting epitopes derived from the melanim-associated antigen MART-1 and gp100, 2000(4)
[18] Su Z, DANNULL J, HEISER A. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. 2003(9)
[19] GongJ, AVIGAN D, CHE N D. Activation of antitumor cytotoxic T lymphocytes by fusion of human dendritic cells and breast carcinoma cells. 2000(6). doi:10.1073/pnas.050587197
[20] Kugler A, STUHLER G, WALDEN P. Regression of human metastatic renal cell earcinoma after vaccination with tumor cell-dendritic cells hybrids. 2000. doi:10.1038/73193
[21] MENG W S, BUTTERFIELD L H, Ribas A. Ration design of peptide-based tumor vaccines. 2002(7). doi:10.1023/A:1016497818471
[22] Wang X Y, CHEN X, MANJILI M H. Targeted immunotherapy using reconstitJuted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gpl00. 2003(10)
[23] MICONNET I, KOENIG S, SPEISER D. CpG are efficient aduvants for specific CTL induction against tumor antigen-derived peptide, 2002(3)
[24] Davila E, CELIS E. Repeated administration of cytosinephosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity, 2000
[25] Sun X, HODGE L M, JONES H P. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. 2002(9/10). doi:10.1016/S0264-410X(1)00476-5
[26] King C A, SPELLERBERG M B, Zhu D. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. 1998(11). doi:10.1038/3266
[27] Rice J, BUCHAN S, STEVENSON F K. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen, 2002(7)
[28] KALAT M, KUPCU Z, SCHULLER S. In vivo plasmid electroporation induces tumor antigen-specific CD8 + T-cell responses and delays tumor growth in a syngeneic mouse melanoma model, 2002(19)
[29] TIMMERMAN J M, SINGH G, HERMANSON G. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. 2002(20)
[30] BARAL R N, SAHA A, CHATTERJEE S K. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics earcinoembryonic antigen, 2003(5) |
